Clinical Trials Logo

Sexual Arousal Disorder clinical trials

View clinical trials related to Sexual Arousal Disorder.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04673708 Completed - Sexual Behavior Clinical Trials

H - Test Usage in Identification of Sexual Orientation Among People.

Start date: December 11, 2020
Phase: N/A
Study type: Interventional

Using of H - test in identifying the sexual behavior of the human.

NCT ID: NCT04566783 Completed - Clinical trials for Sexual Arousal Disorder

Identification of Etiopathological and Clinical Factors in Persistent Genital Arousal Disorder

iPGAD
Start date: June 1, 2020
Phase:
Study type: Observational

Investigation of (possible etiological) factors associated with PGAD symptomatology as well as description of comorbid disorders subjects with PGAD. Persistent genital arousal disorder (PGAD) is a presumably rare, although debilitating condition, which was first defined at the beginning of this century and has not yet found consideration by any of the international classification systems of diseases. PGAD is commonly characterized by persistent and unwanted sensations of genital arousal which are not related to subjective feelings of sexual desire or arousal. Affected patients which are predominantly women can suffer tremendously. The lack of basic research on the etiology of PGAD leads to insufficient therapeutical approaches.

NCT ID: NCT03720743 Completed - Clinical trials for Sexual Arousal Disorder

Effect of Biodanza on Desire, Excitation and Sexual Inhibition

Start date: January 15, 2018
Phase: N/A
Study type: Interventional

the objective of this study was to examine the effects of a 10 weeks biodanza program on the sexual desire and inhibition/arousal of a sample of healthy young adults. A randomized clinical study was carried out, involving a total of 86 young adults divided into Intervention Group (BG) and Control Group (CG), carrying out biodanza sessions during 10 weeks. The Sexual Desire Inventory (SDI) and the Sexual Inhibition/Sexual Arousal-Short Form Scale (SIS/SES-SF) were completed before and after the intervention.

NCT ID: NCT03592121 Completed - Breast Cancer Clinical Trials

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

Start date: July 9, 2018
Phase: Early Phase 1
Study type: Interventional

The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.

NCT ID: NCT02570282 Completed - Clinical trials for Sexual Arousal Disorder

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

Start date: September 2015
Phase: Phase 2
Study type: Interventional

This is a Phase 2, single center, single-dose, double-blind, placebo-controlled, 2-way crossover study to evaluate the safety and efficacy of SST-6007 in women with FSAD. A sufficient number of participants will be enrolled to yield 30 (approximately 15 pre-menopausal and 15 post-menopausal) participants to complete the SST-6007/Placebo Double-Blind, Dosing Phase of the study (Visit 2 and Visit 3).

NCT ID: NCT00746967 Completed - Clinical trials for Sexual Dysfunctions, Psychological

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

Start date: January 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.

NCT ID: NCT00425256 Completed - Clinical trials for Sexual Arousal Disorder

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.